Dr. Nicholas Galakatos is a co-founder and Managing Director of Clarus Ventures, a global venture capital firm focused on life science investments. He has been a venture capital investor since 1992, initially at Venrock Associates and then at MPM Capital where he was General Partner. From 1997-2000 Nick was Vice President, New Business and a member of the Management Team at Millennium Pharmaceuticals (presently Takeda). He was a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he also was the Chairman and founding CEO. Nick entered the venture capital business after being Head of Molecular Biology Research at Ciba (presently Novartis). He holds a B.A degree in chemistry from Reed College, a Ph.D. degree in organic chemistry from MIT, and performed postdoctoral studies in molecular biology at Harvard Medical School.
Nick is a member of the Board of directors of Aveo (NASDAQ: AVEO) and of several private companies including Catabasis, Nanostring, Ophthotech and Portola. Previously, he was the Chairman of TransForm (acquired by J&J) and Hypnion (acquired by Lilly), the Lead Director at Affymax (NASDAQ: AFFY), and a Director of Taligen (acquired by Alexion), Critical Therapeutics (NASDAQ: CRTX), Syrrx (acquired by Takeda), Millennium Predictive Medicine (acquired by Millennium), Millennium BioTherapeutics (acquired by Millennium), and Caliper (NASDAQ: CALP).
In addition to the Leadership Council of the Koch Institute, Nick is also a member of the Genetics Advisory Council at Harvard Medical School.